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CholesterolCardiovascular Disease (CVD) epidemiology varies significantly among Low and Middle-Income
Countries. Honduras is the Central American country with the highest Ischemic Heart Disease and CVD
mortality rates. The aim of this study was to assess the individual CVD risk factors and calculate
Cardiovascular Risk Assessment Scores (CVRAS) from the population. Methods: A cross-sectional study
in western Honduras. Estimation of CV risk was performed using Framingham, MESA, ACC/AHA-PCEs
and ESC SCORE calculators. Results: 38% were male. For men and women respectively; 49% and 48%
had self-reported hypertension (HTN), on measured blood pressure only 18% and 30% had normal read-
ings. Diabetes Mellitus was reported in 19% and 22%. Tobacco use was 14% and 3%. Self-reported regular
exercise was 39.9% and 25%. Obesity was diagnosed in 24% and 24%. Lipid profile; total cholesterol was
200 mg/dl in 63% of subjects. LDL-C was elevated (>100 mg/dl) in 74% of participants, 9% had LDL-C
levels higher than 190 mg/dl. Triglycerides were high (>160 mg/dl) in 60%, of these subjects 22% were
taking lipid-lowering medications. 52% reported family-history of CVD. The risk calculation for men
and women respectively for each CVRAS were; AHA/ACC-PCEs high risk (score  7.5%) in 62% and 30%,
FRS high risk (score  20%) 46% and 15%, MESA high risk (Score  7.5%) in 70.6% and 17.7%, ESC
SCORE high risk (score  5% in 32.4% and 11.8%). Conclusions: CV risk calculations revealed higher than
rates than expected with consequently reflected on higher than estimated CVRAS. This represents the
first report of its kind in Honduras.
 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The incidence and prevalence of Non-communicable Diseases
(NCDs) including Cardiovascular Diseases (CVDs), diabetes, cancer
and chronic respiratory diseases in many Low-and Middle-Income
Countries (LMICs) has risen in recent years [1]. In fact, approxi-
mately 80% of global NCDs mortality occurs in LMICs [2–4]. Theimplementation of strategies to decrease the prevalence and inci-
dence of CVD is a major public health concern [5,6]. For this reason,
it is not only fundamental to understand the epidemiologic charac-
teristics of the population, but most importantly, to develop tools
and strategies to cost-efficiently decrease CVD morbidity and mor-
tality rates considering the economic limitations of LMICs [7].
Latin America is a region with varying epidemiologic data in
CVD, differing significantly among its sub regions [8–10]. Some
countries, including Argentina, Brazil, Chile and Cuba have experi-
enced sustained decreases in CVD mortality rates in the past sev-
eral decades. Conversely, countries like Mexico and some Central
American countries have increasing trends in CVD mortality [6].
Therefore, developing generalizable approaches to tackle CVD in
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among different LMICs due in part to genetic, racial, social and cul-
tural diversity [11]. Accordingly, it is imperative that concerted
efforts are made to better understand the needs and risk of each
population separately.
Central America is a sub-region with few epidemiologic studies
in CVD. Honduras is the Central-American country with the highest
Ischemic Heart Disease (IHD) and CVDmortality rates for both men
and women, as well as disability-adjusted life years (DALYs) due to
CVD burden [12–14]. Most of Honduras’ recent epidemiologic
studies on CVD have been obtained from few cross-sectional stud-
ies. However, there is no data from longitudinal studies. As in the
rest of LMICs, coordinated inter-institutional efforts need to be
made in Honduras to cost-efficiently direct the scarce resources
to help decrease the burden of CVD [15]. Stratification of high-
risk patients according to their cardiovascular (CV) risk is one of
the fundamental strategies to decide which are the most beneficial
cost-effective measures to decrease CVD morbidity and mortality
[16].
In this study we aim to provide a current epidemiologic per-
spective of the CVD burden in Copan, which is the most populated
department in Western Honduras with a population of nearly four
hundred thousand inhabitants, predominantly Hispanic/mestizo
and indigenous population living mainly in rural areas. The main
long-term objective of this study is to follow this cohort to further
analyze their epidemiologic characteristics and gain a deeper
understanding of CVD burden in Honduras. Our second objective
is to estimate CVD risk in this population using various risk scores
to determine which are most suitable for risk estimation in this
population.2. Methods
2.1. Population sample
A cross-sectional descriptive study of the resource limited set-
ting of Western Honduras of random volunteers between 45 and
75 years, of both genders, who were seen by medical doctors in
both public and private medical institutions in the Department
(state) of Copán, Honduras, between November 2016 and January
2017. The study was promoted through the area to ensure catch-
ment from the whole department. The physicians who participated
were all educated about the study design
The Honduran National Institute of Statistics has a registered
census of the adult population of the department of Copán ranging
from 45 to 75 years old (N = 57,299 inhabitants), which represents
the universe of the study. We hypothesized a difference between
proportions of males and females with effect size (d = 0.1). In order
to achieve a power of 0.8, the sample calculated for a 95% CI with a
maximum error of 0.05, corresponded to 382 patients which were
recruited randomly within the area.
The protocol, informed consent and study procedures and mea-
surements were approved by the Western Hospital Ethics Commit-
tee (FWA: 00000669/IRB 00001470). The criteria for patients to be
included in the study were: age between 45 and 75 years, both gen-
ders, living in the Department of Copan, with prior consent to be
included in the study. The exclusion criteria were past medical his-
tory of cardiovascular disease; Myocardial Infarction (MI), Angina,
Cerebrovascular Accident/Transient Ischemic Attack (CVA/TIA),
Congestive Heart Failure (CHF), Atrial Fibrillation (AF), cardiac
catheterization, ongoing cancer treatment, pregnancy, weight more
than 300 lb ***or cognitive disability to participate in the study.
An instrument was developed to obtain information prior
informed consent from each patient which included: patient gen-
eral information, past medical history, past family history, use oftobacco, medications (lipid-lowering, anti-diabetic and anti-
hypertensive), physical activity, blood pressure (BP), Body Mass
Index (BMI), hip-waist ratio, glucose, triglycerides, total choles-
terol, HDL-cholesterol (HDL-C), and LDL-cholesterol (LDL-C).2.2. Risk factor assessment
The patients included in the study were either referred to a clin-
ical laboratory or voluntarily attended the clinic/laboratory com-
plex where they were examined, measured and tested by
certified health professionals. After informed consent, blood pres-
sure was taken by a medical doctor with a Welch Allyn sphygmo-
manometer, appropriately sized cuffsand a Littman classic II
stethoscope. After 5 min, the instrument was filled and then a sec-
ond BP measurement was taken. The average of 2 BP measure-
ments was registered.
An analogous calibrated scale was used to determine weight
and height following the clinical method according to the Frankfort
plane (patient standing up with head in horizontal position), calcu-
lating the BMI. A soft tape measure (ADC Woven) was used to
measure the abdominal and hip circumferences to calculate the
hip-waist ratio. Laboratory analysis was carried using HumaStar
200 (HUMAN Germany) using enzymatic colorimetric assay for
all tests.2.3. Risk estimation
The cardiovascular risk for each participant in the study was
estimated using 3 cardiovascular disease risk assessment scores;
MESA risk score, Framingham risk score (FRS), the Pooled Cohort
Equations (PCEs) of the AHA/ACC and ESC SCORE risk score [17–
19]. These scores use CV risk factors to predict the probability of
having hard CV outcomes in 10 years such as Coronary Heart Dis-
ease (CHD) and/or Stroke. For FRS and MESA the CV outcome is
Coronary Heart Disease (CHD) while PCEs also includes stroke.
All of the CVRAS focus mainly on traditional CV risk factors, but
each of them have unique features. MESA for instance, was based
on a study which included approximately 1600 patients of multi-
ple ethnicities with sufficiently pondered African-American and
Hispanics populations. Optionally, it can incorporate the measure-
ment of Coronary Artery Calcium (CAC) Score.
PCEs also adjusts for African-Americans or ‘‘Other” races and
incorporates new factors such as being on antihypertensive medi-
cations. FRS has the known limitation of being designed from a
highly predominant Caucasian study population. Patients will be
followed up for 10 years to asses the development of CVD or stroke.
By actively searching morbidity and death records at the national
registry.2.4. Statistical analysis
All data was captured via REDCap (Research Electronic Data
Capture) which is a secure, web-based used for a variety of types
of research and provides easy data manipulation with an auto-
mated export mechanism to common statistical packages (SPSS,
SAS, Stata, R/S-Plus). REDCap servers are housed in a local data cen-
ter at Vanderbilt, and all web-based information transmission is
encrypted.
Data was analyzed using STATA 14. Continuous variables were
reported as means and standard deviations (SD); categorical vari-
ables as frequencies with their respective percentage. Wilcoxon
rank-sum was employed for continuous variables hypothesis test-
ing and Pearson’s chi-squared was used for categorical variables.
The threshold selected for statistical significance was 0.05.
Table 1
Basic Characteristics (n = 382).
Characteristic N (%)
Age, mean ± SD 58 ± 7.9
Sex
Male 145 (38)
Female 237 (62)
BMI
<18.5 - Underweight 2 (0.5)
18.5–24.9 - Normal 116 (30.4)
25–29.9 - Pre-obese 172 (45.0)
30–34.9 - Obese Class I 73 (19.1)
35–39.9 - Obese Class II 12 (3.2)
>40 - Obese Class III 7 (1.8)
Abdominal circumference, mean ± SD 95.1 ± 11
Blood Pressure (mmHg)
Normal 98 (25.7)
Pre-Hypertension 155 (40.6)
Stage 1 HTN 89 (23.3)
Stage 2 HTN 40 (10.4)
Self-reported Tobacco use 28 (7.3)
Self-reported Exercise 114 (29.8)
Blood Glucose (mg/dL)
<126 316 (82.9)
126–199.9 43 (11.3)
200 22 (5.8)
Values are n, n (%), or mean ± SD, Normal = SBP < 120 mmHg &
DBP < 80 mmHg, Pre-hypertension = SBP = 120–129 mmHg &
DBP < 80 mmHg, Stage 1 HTN = SBP = 130–139 mmHg or
DBP = 80–89 mmHg, Stage 2 HTN = SBP  140 mmHg or
DBP  90 mmHg.
Abbreviations: BMI = Body Mass Index, HTN = Hypertension.
Table 2
Blood Preasure Lowering Treatment (n = 382).
Blood Pressure Not on Treatment
(n = 212)
On Treatment
(n = 170)
Normal 73 (34.4) 25 (14.7)
Pre-Hypertension 90 (42.5) 65 (38.2)
Stage 1 HTN 39(18.4) 50 (29.4)
Stage 2 HTN 10 (4.7) 30 (17.7)
Values are n, n (%), Normal = SBP < 120 mmHg & DBP < 80 mmHg, Pre-hyperten-
sion = SBP = 120–129 mmHg & DBP < 80 mmHg, Stage 1 HTN = SBP = 130–
139 mmHg or DBP = 80–89 mmHg, Stage 2 HTN = SBP  140 mmHg or
DBP  90 mmHg.
Abbreviations: SBP = Systolic Blood Preasure, HTN = Hypertension, DBP = Diastolic
Blood Preasure.
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Voluntary attendance and referrals ranged between five to ten
patients each day. 384 patients were found eligible and went
through examination and testing. Two of these patients were
removed from the final analysis due to missing or conflicting data
(BP, cholesterol and BMI). The final analysis sample was 382; 145
(38%) male and 237 (62%) female.
3.1. Subject characteristics
Mean age was similar between both genders (57 and 58 years
for men and women, respectively, P = 0.31). Among the selected
sample, all male subjects except one, and all women were from
Hispanic/Latino descent. Approximately 80% of subjects resided
in Santa Rosa de Copán, the capital city of the department (state),
followed by nearby rural towns: San Juan de Opoa and Corquín,
each with approximately 4%. Self-reported family history of cardio-
vascular disease (stroke, myocardial infarction, PAD) was 52.9%,
while family history of myocardial infarction was 31.3%.
3.2. Prevalence of self-reported cardiovascular risk factors
Prevalence of hypertension was 49.7% and 47.7% among men
and women respectively (see Table 1). 91.3% of diagnosed subjects
were currently taking anti-hypertensive medication. Self-reported,
previously diagnosed diabetes mellitus ranged from 19% in men to
22.1% in women; 95.7% of these were currently being treated.
Tobacco consumption was significantly higher among men, 14%
versus 3.4% in women. Self-reported regular physical activity (de-
fined as moderate aerobic physical activity for at leas 150 min a
week ‘‘30 min a day for 5 days a week or 75 min a week of vigorous
aerobic physical activity) was 39.9% in men, while only 24.5% of
women reported exercising regularly.
3.3. Prevalence of measured cardiovascular risk factors
Mean body mass index measurements were similar between
both genders (27.4 kg/m2 for males and 27.34 kg/m2 for females).
Obesity (BMI > 30 kg/m2) was 24.3% among males and 23.9%
among females. However, only 31% of subjects were recorded to
have a normal or underweight (BMI < 24.9 kg/m2). Abdominal obe-
sity was more prevalent in women (65.4%) compared to men
(34.9%) (p < 0.001) (see Table 1).
The average of two blood pressure measurements was used for
analysis (Table 1). Only 18.2% of males and 29.5% of females had
normal blood pressure measurements. More than a third of all par-
ticipants had either stage 1 or stage 2 hypertension. Even though
44.5% of all participants admitted taking blood pressure lowering
medication, 43.8% of patients in stage 1 and 25% of stage 2 were
not taking any medication. (p < 0.0001). Furthermore, 42.5% of sub-
jects in stages 1 or 2 did not have a previous diagnosis of hyperten-
sion. (p < 0.0001). From all patients on blood pressure lowering
treatment n = 170 (44.5%), almost half (47.1) had blood pressures
corresponding to Stage 1 or 2 (SBP  130 or DBP  80) (see
Table 2).
Fasting blood glucose was abnormal (>125 mg/dl) in 11.6% of
subjects; 5.5% were above 200 mg/dl. 6.7% of subjects had abnor-
mal glucose measurements without a previous diagnosis of dia-
betes. 63.1% of subjects had cholesterol measurements above
200 mg/dl; there was a similar distribution between genders.
Distribution of LDL-C categorization was similar between both
genders (Table 3). 74.2% had LDL-C levels above 100 mg/dl. LDL-
C was equal or higher than 190 mg/dl in 9.2% of patients, however
only 22% of subjects in this subgroup were taking lipid-loweringtreatment (Table 4). Triglyceride levels were high in 60% of the
subjects studied. Levels higher than 500 mg/dl were more preva-
lent in men (7.7%) than women (2.1%).3.4. Risk stratification
Male sex, being a CV risk factor per se, significantly skewed
male-female percentage risk of all cardiovascular risk scores
tested. Mean of MESA risk score among men was 12.8 ± 8.4,
women 4.5 ± 5.2. FRS calculation yielded 95% of men scored > 6%
of risk, and 46.5% are classified as high risk (score > 20%), among
females, only 15% were above the high risk cut point (score > 20%).
ACC/AHA-PCEs was above 7.5% in 62% of men and 29.8% of women.
ESC SCORE was calculated with 20% of participants had a high-risk
score (>5%) 47% and 28% for males and females respectively
(Table 5).4. Discussion
To our knowledge, this is the first observational study of CVD
risk factors in Western Honduras. We note several important
Table 3
Lipid Profile (n = 380*).
Male
(n = 143)
Female
(n = 237)
p-value
Total Cholesterol (mg/dL)
<200 56 (39.2) 84 (35.4) 0.76
200–239.9 45 (31.5) 80 (33.8)
240 42 (29.4) 73 (30.8)
LDL-c (mg/dL)
<100 - Optimal 38 (26.6) 60 (25.3) 0.98
100–129.9 - Above optimal 36 (25.2) 66 (27.8)
130–159.9 - Borderline high 40 (28.0) 62 (26.2)
160–189.9 - High 16 (11.2) 27 (11.4)
190 Very high 13 (9.1) 22 (9.3)
HDL-c (mg/dL)
<40 - Low 59 (41.3) 64 (27.0) 0.016
40–59.9 - Sub-optimal 70 (49.0) 144 (60.8)
60 - Max-optimal 14 (9.8) 29 (12.2)
Triglycerides (mg/dL)
<150 - Normal 49 (34.3) 96 (40.5) 0.052
150–199.9 - Borderline high 33 (23.1) 50 (21.1)
200–499.9 - High 50 (35.0) 86 (36.3)
500 -Very high 11 (7.7) 5 (2.1)
Values are n, n (%), or mean ± SD.
*Complete lipid profile for 2/382 patient were not adequately processed.
Abbreviations: LDL-c = Low-density Lipoprotein – Cholesterol, HDL-c = High-den-
sity Lipoprotein – Cholesterol.
Table 4
LDL-c and Lipid-Lowering Treatment (n = 380).
Not on Treatment
(n = 283)
On Treatment
(n = 95)
p-value
Total LDL-c (mg/dL)
<100 Optimal 68 (24.0%) 30 (31.6%) 0.20
100–129.9 Above optimal 73 (25.8%) 29 (30.5%)
130–159.9 Borderline high 83 (29.3%) 17 (17.9%)
160–189.9 High 32 (11.3%) 11 (11.6%)
190 Very high 27 (9.5%) 8 (8.4%)
Values are n, n (%), or mean ± SD.
Abbreviations: LDL-c = Low-density Lipoprotein – Cholesterol.
Table 5
Cardiovascular Risk Assessment Scores (n = 380).
Male
(n = 143)
Female
(n = 237)
p-value
MESA risk score
<7.5% risk 42 (29.4) 195 (82.3) <0.001
7.5% risk 101 (70.6) 42 (17.7)
Framingham risk score
<6% risk 7 (5.0) 81 (34.6) <0.001
6–19% risk 69 (48.9) 118 (50.4)
>20% risk 65 (46.1) 35 (15.0)
AHA/ACC-PCEs Score
<7.5% risk 52 (38.0) 158 (70.2) <0.001
7.5% risk 85 (62.0) 67 (29.8)
ESC SCORE
<5% risk 98 (67.6) 209 (88.2)
5% risk 47 (32.4) 28 (11.8) <0.001
Values are n, n (%), or mean ±
Abbreviations: MESA = Multi-Ethnic Study of Atherosclerosis AHA/ACC-
PCEs = American Heart Association – Pooled Cohort.
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betes are markedly elevated (nearly 50% and 20% respectively)
which is higher than the prevalence in developed as well as some
other Latin American countries. (2) There were notable differences
in health behaviors and risk factors among men and women
including obesity rates (65% for women compared to 35% for
men), and smoking (3% for women vs 14% for men). (3) Cholesterolis grossly undertreated for the highest risk patients. Only 95 out of
382 patients (24.9%) were taking lipid-lowering medications, out
of the very high LDL-c group (n = 95) only 8% (n = 8) were on treat-
ment) Hypertension is grossly undertreated with only one quarter
of patients with diagnosed hypertension having a SBP < 120 and
DBP < 80 mmHg. 5) ASCVD risk estimation varied between differ-
ent risk scores but was alarmingly elevated in all cases.
This early study in western Copán provides several novel
insights on CVD risk factor prevalence in the region. Santa Rosa
de Copán is a small but partially urbanized city and the commercial
center of Western Honduras due to its proximity to the Guatemala
and El Salvador borders. Most of its population is comprised of His-
panic/Mestizo and indigenous descent, which is representative of
the whole country [20]. Prevalence of family history of myocardial
infarction, was found to be similar to what has been previously
reported in the Latin American region [21]. However, family his-
tory of CVD (stroke, PAD, or MI) was 10–20% higher than previous
Latin American studies [22,23].
Worldwide burden of hypertension is approximately 43.9%
among the age groups hereby studied, however, in Latin America
it can be as high as 61.7% in men and 39% in women [24]. Estima-
tions account for >10% increase in the following 25 years in this
region. Among the participants in this study, self-reported hyper-
tension varied significantly from actual blood pressure measure-
ments. While approximately half of participants reported being
previously diagnosed with hypertension, only one quarter of
patients had normal blood pressure, defined as <120/<80. >70% of
males and>50% of females had abnormal blood pressure measure-
ments. Decreased screening frequency, absence of symptoms, or
negativity regarding regular healthcare may account for the under-
diagnosed population.
It is estimated that by 2025, 8.1% of the Latin American popula-
tion will be diabetic [25]. Cities in the region such as Mexico City
and Bogota reach almost 10% [26]. The last reported nationwide
estimation of Honduran diabetics was 7.6% [27]. Diet westerniza-
tion may account for accelerated incidence of diabetes in Latin
America [28]. 21% of our subjects had a previous diagnosis of dia-
betes, however 6.7% of subjects not previously diagnosed had
abnormal glucose measurements, 1.8% of them with readings over
200 mg/dl.
Latin America comprises a heterogeneous mixture of smoking
prevalence ranging from 2 to 3% in Costa Rica to 52% in Peruvian
males [29]. Santa Rosa de Copan was the first trading post were
the Spanish crown established a royal tobacco trading post in
1765 [30]. Since then, tobacco production has declined; less than
1% of agricultural land is devoted to tobacco growing. Honduras’
nationwide smoking prevalence was previously estimated to be
36% in males and 11% in females [29]. However, our contemporary
data sample demonstrated less than half of those prior estimates;
which could be attributed to increased awareness of disease, med-
ical recommendation or higher age in the sample studied.
Western high-fat/calorie diets at low prices have become
increasingly popular in LMICs (Low and Middle-Income Countries).
The additive effect of physical inactivity –less than 40% in men and
less than 25% in women in our sample reported being physically
active– feeds into other cardiovascular risk factors. In 1996, Hon-
duras was the country with the smallest percentage of obese or
overweight population in the region, but today more than half of
the adult population is overweight [31]. Obesity, a CV risk factor
itself, is associated with increased incidence of diabetes, stroke,
dyslipidemia and increased overall mortality. Abdominal obesity
correlated with previously reported data in Latin American popula-
tions (60% in females, 35% in males) [32]. However, some experts
have suggested that visceral obesity and therefore increased car-
diovascular risk, may present with lower abdominal circumference
cutoffs in non-Caucasian populations [33,34].
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LDL-C levels have been correlated with increased cardiovascular
risk. Recent guidelines propose an aggressive treatment of elevated
LDL-C levels. Compared to other Latin American cities, hyperc-
holesterolemia prevalence was twice as high [35]. Similarly, LDL-
C levels above 160 mg/dl ranged from 4% to 11% in the CARMELA
dyslipidemia study [36]. Our sample presented with 20.5% preva-
lence above this threshold, with half of these subjects above
190 mg/dl. According to widely accepted predictive models, hyper-
tension and dyslipidemia are fundamental in CHD development
[37]. This might shed some light onto the mechanisms for CVD
causality in this region.
CVRAS are important tools in current clinical practice for the
management of cardiovascular diseases. They have an even more
significant role in resource-limited countries due to their useful-
ness in risk-stratifying populations and identifying high-risk
patients for more focused, cost-effective individual and
population-based interventions [36]. For the past few decades,
the Framingham Risk Score has been the most widely used score
and it has been validated in many countries [38]. In 2013, the PCEs
risk score of the AHA/ACC Assessment of Cardiovascular Risk
guidelines became the most used CV risk assessment score in the
United States [19]. The MESA risk score in particular, has been
designed based on a racially-diverse population, therefore it takes
into account Hispanics living in the USA [39].
These scores however, have been derived from studies based on
populations in the United States, impeding their generalization and
applicability to LMICs in Latin American with different races and
ethnicities such as Honduras. Studies have been made to either
recalibrate these scores to specific populations or to develop differ-
ent scores such as INTERHEART or the WHO/ISH cardiovascular
risk prediction model [40,41].
Our study revealed an alarming proportion of high-risk patients
according to all three scores. For men and women respectively;
ten-year ASCVD risk by the AHA/ACC-PCE was >7.5% in 62% and
29.8%. CHD riskby FRS was >20% in 46.1% and 15%, and ten-year
CHD risk by the MESA Risk Score was >7.5% in 70.6% and 17.7%.
According to this, there is a large high-CV-risk population in Hon-
duras which is of significant public health concern. Most impor-
tantly, it points to a vast population of undiagnosed and
untreated/inappropriately treated population for CV risk factors
such as hypertension and hyperlipidemia.
However, multiple studies have shown an overestimation of
predicted CV events of both FRS and PCEs in Hispanics living in
USA as well as in Hispanics in some Latin American countries
[42,43]. Being the first study of its type in Honduras, there are cur-
rently no studies to compare these results with. Efforts should be
made to follow-up this study sample as a cohort in a longitudinal
study to assess outcomes such as Major Adverse Cardiovascular
Events (MACEs) and CV mortality which could be an opportunity
to either recalibrate or validate these scores for the Honduran pop-
ulation, this done by continuously revising morbidity records and
death records at the national registry for at least 10 years and add-
ing the data to the already existing database.5. Conclusions
This study has provided novel data about Western Honduras CV
epidemiology and Honduras in general. Most importantly, it has
revealed data which is unique to the Honduran population as com-
pared to studies from other countries in the region and which adds
to the concept of widely varying CV epidemiology within the dif-
ferent Latin American countries. Risk factors such as hypertension,
diabetes and high cholesterol where markedly higher in our study
population as compared to developed and some other Latin Amer-ican countries. Many patients at high CVD risk were receiving inad-
equate treatment of their blood pressure and lipids. These findings
translate to alarmingly elevated CVRAS, with an elevated propor-
tion of high-risk patients in all 3 scores used (PCEs, FRS, MESA).
This raises significant public health concern and underscores the
importance of continued observational data and concerted public
health efforts to aggressively reduce CVD risk in the region.6. Limitations
The limitations of this kind of studies in LMIC settings are
mainly due to the lack of some variables necessary for risk calcula-
tion in the population (lipid profile, renal function), lack of com-
puterized risk calculators and the difficulty to follow-up
volunteers in a setting with massive migration. At the moment of
the study random sampling of volunteers were enrolled in which
surprisingly accounted for a higher proportion of male participants
>60% this may have been avoided by doing stratified sampling. This
might result in selection bias, but we have to make the best use of
the results acquired so we still interpret it for the population in
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